@article{ref1,
title="Changes in the serotonin transporter in the hippocampus of subjects with schizophrenia identified using [3H]paroxetine",
journal="Journal of neural transmission",
year="1996",
author="Naylor, L. and Dean, B. and Opeskin, K. and Pavey, G. and Hill, C. and Keks, N. and Copolov, D.",
volume="103",
number="6",
pages="749-757",
abstract="[3H]paroxetine binding to membrane from hippocampus, obtained at autopsy, from 24 schizophrenic and 24 non-schizophrenic subjects has been measured. The affinity of [3H]paroxetine binding to hippocampal membrane was decreased in subjects with schizophrenia (Kd = 0.50 +/- 0.04 vs. 0.24 +/- 0.02nM; mean +/- S.E.M. p < 0.001) but was not different in schizophrenic subjects who had or had not committed suicide (Kd = 0.50 +/- 0.07 vs. 0.50 +/- 0.04nM). The density of [3H]paroxetine binding sites did not differ between the schizophrenic and non-schizophrenic subjects. For the schizophrenic subjects, there was no relationship between ante-mortem neuroleptic drug treatment and [3H]paroxetine binding to the hippocampal membrane. Finally, this study has shown that neuroleptic drug treatment of rats does not alter [3H]paroxetine binding to the hippocampal membranes. Thus, it would seem that the changes in the affinity of [3H]paroxetine binding to the hippocampus of schizophrenic subjects are not likely to be due to neuroleptic drug treatment but may be involved in the pathology of the illness.<p /><p>Language: en</p>",
language="en",
issn="0300-9564",
doi="10.1007/BF01271234",
url="http://dx.doi.org/10.1007/BF01271234"
}